FLUMIST, FLUMIST QUAD Drug Profile
Summary for Tradename: FLUMIST, FLUMIST QUAD
| High Confidence Patents: | 3 |
| Applicants: | 1 |
| BLAs: | 1 |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for FLUMIST, FLUMIST QUAD Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for FLUMIST, FLUMIST QUAD Derived from DrugPatentWatch Analysis and Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Medimmune, Llc | FLUMIST, FLUMIST QUAD | influenza vaccine live, intranasal | Suspension | 125020 | ⤷ Start Trial | 2018-04-06 | DrugPatentWatch analysis and company disclosures |
| Medimmune, Llc | FLUMIST, FLUMIST QUAD | influenza vaccine live, intranasal | Suspension | 125020 | ⤷ Start Trial | 2021-04-11 | DrugPatentWatch analysis and company disclosures |
| Medimmune, Llc | FLUMIST, FLUMIST QUAD | influenza vaccine live, intranasal | Suspension | 125020 | ⤷ Start Trial | 2022-05-02 | DrugPatentWatch analysis and company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for FLUMIST, FLUMIST QUAD Derived from Patent Text Search
No patents found based on company disclosures
FluMist and FluMist Quadrivalent Market Dynamics, Financial Trajectory, and Patent Outlook
FluMist is AstraZeneca’s live attenuated influenza vaccine and the only needle-free influenza vaccine marketed in the United States. Its commercial position improved after the 2018 restoration of U.S. recommendations for eligible patients and strengthened materially in 2024 when the FDA authorized self-administration for people ages 2 through 49. The product remains a seasonal, lower-volume vaccine rather than a core revenue driver for AstraZeneca. Its principal growth opportunity is broader access through pharmacies, telehealth, schools, employers, and direct-to-consumer distribution.
What are FluMist and FluMist Quadrivalent?
FluMist is a live attenuated influenza vaccine administered intranasally. FluMist Quadrivalent was designed to protect against four influenza strains, two influenza A strains and two influenza B strains. AstraZeneca markets the product in the United States; AstraZeneca AB is the manufacturer named in FDA materials.
| Product | Technology | Route | U.S. age range | Regulatory status |
|---|---|---|---|---|
| FluMist | Live attenuated influenza vaccine | Intranasal spray | 2 to 49 years, subject to labeling | FDA-approved |
| FluMist Quadrivalent | Quadrivalent live attenuated influenza vaccine | Intranasal spray | 2 to 49 years, subject to labeling | FDA-approved |
| Fluzone, Fluarix, Afluria, others | Inactivated or recombinant vaccines | Injection | Varies by product | FDA-approved |
FluMist differs from most influenza vaccines because it does not require an injection. That distinction creates a distribution advantage in settings where needle avoidance, convenience, or rapid administration affects uptake.
The product is a biological vaccine rather than a conventional small-molecule drug. Its regulatory and competitive profile is therefore governed primarily by biologics, vaccines, manufacturing controls, annual strain updates, and seasonal procurement.
How did FluMist reach the current market?
The FDA approved FluMist in 2003. The original product was trivalent. AstraZeneca later developed FluMist Quadrivalent, which received FDA approval in 2012. The quadrivalent product became the primary U.S. formulation as influenza vaccine recommendations shifted toward four-strain protection.
A significant commercial setback occurred in 2016, when the Advisory Committee on Immunization Practices recommended against using live attenuated influenza vaccine because of concerns about effectiveness against circulating H1N1 strains. The recommendation was restored for the 2018-2019 season after updated evidence and manufacturing changes. That interruption damaged provider familiarity, purchasing patterns, and patient adoption.
Key regulatory milestones
| Date | Event | Commercial effect |
|---|---|---|
| 2003 | FDA approved FluMist | Established the first U.S. intranasal influenza vaccine |
| 2012 | FDA approved FluMist Quadrivalent | Expanded strain coverage |
| 2016-2017 season | ACIP recommended against LAIV use | Reduced demand and weakened provider adoption |
| 2018-2019 season | ACIP restored LAIV as an option | Reopened the U.S. market |
| 2024 | FDA authorized self-administration for eligible individuals ages 2 to 49 | Expanded access beyond traditional clinical administration |
| 2024-2025 season | First commercial season with the new self-administration option | Created a new pharmacy, telehealth, and household-use channel |
What is the current market opportunity for FluMist?
The U.S. influenza vaccine market is large but highly seasonal and price competitive. Annual U.S. influenza vaccine distribution has generally reached more than 150 million doses in stronger seasons, although volume varies with disease severity, public concern, recommendations, production, and insurance coverage.[1]
FluMist has historically represented a small portion of total U.S. influenza vaccination. Its share is constrained by several factors:
- The product is limited to eligible people ages 2 through 49.
- It is unsuitable for certain immunocompromised individuals and other labeled populations.
- Some clinicians and parents prefer injectable vaccines.
- Influenza vaccination is concentrated into a short procurement and administration window.
- Live attenuated vaccine performance varies by circulating strain and season.
- Pediatric vaccination is influenced by school requirements and pediatric-office workflow.
The 2024 self-administration authorization changes the addressable channel more than the biological market. It allows eligible consumers to receive FluMist without an in-person clinician administering the dose, although the product remains prescription-only. That status preserves a role for pharmacists, telehealth providers, and other authorized prescribers.
Which channels are most important?
| Channel | FluMist opportunity | Main constraint |
|---|---|---|
| Pediatric offices | Familiarity with pediatric nasal delivery | Limited appointment capacity during flu season |
| Pharmacies | Convenient adult and family access | Prescription and age restrictions |
| Telehealth | Supports remote screening and prescribing | Requires fulfillment and administration controls |
| Schools | High-volume pediatric vaccination | State, district, and program approval requirements |
| Employers | Needle-free option for younger workers | Employee age eligibility |
| Direct household use | New post-2024 opportunity | Prescription access and patient instructions |
The strongest near-term growth case is channel expansion, not a large increase in the total influenza vaccine market.
What is FluMist’s financial trajectory?
AstraZeneca does not consistently disclose FluMist revenue as a separately reported major product line in its principal financial reporting. As a result, investors cannot reliably calculate annual FluMist revenue, gross margin, or operating profit from AstraZeneca’s consolidated filings alone.[2]
The product’s financial trajectory is best understood through commercial phases:
| Period | Financial direction | Principal driver |
|---|---|---|
| 2003-2015 | Initial adoption followed by modest seasonal growth | Differentiated needle-free positioning |
| 2016-2017 | Sharp contraction | ACIP recommendation against LAIV |
| 2018-2023 | Recovery, but from a reduced base | Reinstated recommendation and market re-entry |
| 2024 onward | Potential structural improvement | Self-administration and expanded channels |
FluMist’s economics have several favorable characteristics. It uses a differentiated delivery system, avoids needles, and can command value in settings where administration convenience matters. Self-administration also has the potential to reduce provider labor and expand utilization outside physician offices.
The product has offsetting cost and risk factors. Influenza vaccines require annual strain selection and production planning. Unused inventory can become obsolete after the season. Demand forecasts are difficult because vaccination behavior changes with disease intensity, public health messaging, and competing respiratory viruses. Manufacturing a live attenuated vaccine also requires specialized biological controls and validated cold-chain handling.
Is FluMist material to AstraZeneca’s revenue?
FluMist is strategically relevant but unlikely to be material to AstraZeneca’s consolidated revenue compared with products such as Tagrisso, Farxiga, Imfinzi, Ultomiris, and other major medicines. AstraZeneca reports revenue across broad product and therapeutic categories, while seasonal vaccine revenue generally has lower visibility and greater quarter-to-quarter volatility.[2]
The 2024 regulatory expansion can improve the product’s growth rate without making FluMist a major contributor to group sales. The most likely financial outcome is a moderate increase in seasonal revenue and improved channel economics rather than a transformation into a billion-dollar franchise.
What patents protect FluMist and FluMist Quadrivalent?
FluMist’s commercial protection does not resemble the patent structure of a new small-molecule medicine. The product’s original composition and cold-adapted influenza technology were developed many years ago. Core technology patents associated with early live attenuated influenza vaccine platforms are likely expired or approaching the end of ordinary patent life, depending on the specific patent, priority date, patent-term adjustment, and jurisdiction.
The main current barriers are more likely to be:
- Manufacturing know-how for live attenuated strains.
- Master and working seed systems.
- Biological assays and release specifications.
- Strain selection and annual production processes.
- Regulatory history and manufacturing validation.
- Distribution relationships and seasonal contracting.
- Brand recognition among pediatric providers and pharmacies.
Does FluMist have Orange Book protection?
The Orange Book is not the principal patent reference for FluMist because FluMist is a biologic vaccine approved under a biologics license application rather than a conventional small-molecule new drug application. The FDA’s Purple Book is the more relevant biologic reference, but it does not create the same patent-listing framework used for many Orange Book drugs.[3]
FluMist also does not face the standard generic substitution model used for small-molecule medicines. A competing manufacturer would generally need to pursue an appropriate biologics or vaccine approval pathway, establish product comparability or clinical support, and meet stringent manufacturing and lot-release requirements.
When does FluMist lose exclusivity?
FluMist’s principal statutory biologic exclusivity period has already elapsed. The FDA approved the product in 2003, well before the modern 12-year reference-product exclusivity framework under the Biologics Price Competition and Innovation Act became operational for newly licensed reference products. Patent protection, if any remains for specific improvements, must be assessed patent by patent.
There is no single publicly prominent expiration date that eliminates all commercial protection for FluMist. The practical exclusivity position depends on:
- Whether a competitor can reproduce the live attenuated strains.
- Whether it can obtain a U.S. biologics license.
- Whether manufacturing capacity is available.
- Whether the product can be supplied reliably for the annual season.
- Whether providers and payers will accept the competing vaccine.
- Whether the competitor can manage annual strain updates.
The absence of a large remaining core patent moat does not imply immediate market entry. Vaccine manufacturing and seasonal procurement can be stronger barriers than expired platform patents.
Are there Paragraph IV challenges to FluMist?
No standard Paragraph IV litigation profile is associated with FluMist comparable to major oral drugs listed in the Orange Book. Paragraph IV certifications apply to abbreviated new drug applications challenging patents listed for an NDA. FluMist is a biologic vaccine, and the relevant competitive pathway is not the conventional ANDA-Paragraph IV model.
A competitor could still challenge patent rights or seek approval for a competing influenza vaccine, but that dispute would likely involve biologics regulation, patent infringement, manufacturing, or regulatory exclusivity rather than a routine generic-drug Paragraph IV case.
Is there biosimilar risk for FluMist?
Biosimilar risk is currently limited. A competing live attenuated influenza vaccine would face technical and regulatory issues that differ from those for many therapeutic monoclonal antibodies.
Key barriers to a competing product
- Live-virus strain construction and attenuation.
- Demonstration of genetic and phenotypic stability.
- Consistent potency and identity testing.
- Validation of nasal delivery characteristics.
- Annual strain replacement and regulatory review.
- Pediatric safety requirements.
- Specialized manufacturing facilities.
- Short seasonal selling windows.
- Need for dependable supply across multiple strains.
A competitor could target the same clinical need with a different delivery system, including injectable inactivated, recombinant, or cell-based vaccines. Those products compete with FluMist commercially but are not biosimilar versions of FluMist.
Which companies challenge FluMist commercially?
FluMist competes with the major U.S. influenza vaccine manufacturers rather than with a direct nasal-vaccine biosimilar.
| Company | Relevant products | Competitive position |
|---|---|---|
| Sanofi | Fluzone and related influenza vaccines | Large U.S. vaccine supplier with broad age coverage |
| GSK | Fluarix and related products | Established retail and provider distribution |
| CSL Seqirus | Afluria, Fluad, cell-based and adjuvanted products | Strong influenza specialization and differentiated formulations |
| Moderna and other developers | Emerging next-generation influenza platforms | Potential future competition from mRNA or other technologies |
| AstraZeneca | FluMist and FluMist Quadrivalent | Only established U.S. intranasal influenza option |
The most direct competitive threat is not a generic FluMist copy. It is a more effective, more convenient, or easier-to-distribute influenza vaccine that captures pediatric and younger-adult demand.
What formulation and method-of-use rights protect FluMist?
FluMist’s commercial differentiation is tied to its intranasal live attenuated formulation and administration system. Potentially relevant intellectual property categories include:
- Cold-adapted and temperature-sensitive viral strains.
- Reassortant strain composition.
- Stabilizers and excipients.
- Nasal spray device design.
- Storage and thawing conditions.
- Manufacturing methods.
- Potency and identity assays.
- Pediatric administration methods.
- Self-administration protocols and labeling-related know-how.
The 2024 self-administration authorization is a regulatory and commercial expansion, not necessarily a new patent-created monopoly. Its value comes from changing who may administer the vaccine and where the transaction can occur.
What is the FDA regulatory status of FluMist?
The FDA authorized FluMist for self-administration by eligible individuals ages 2 through 49 in 2024. The authorization expanded use from administration by a health-care provider to a model in which the product can be prescribed and administered by the patient or caregiver under the authorized instructions.[4]
The change does not remove prescription requirements or eliminate the product’s contraindications and precautions. It also does not make FluMist suitable for every age group or every patient who seeks influenza vaccination.
The FDA action supports:
- Mail-order fulfillment after remote prescribing.
- Pharmacy-based prescribing and dispensing.
- Household administration for eligible family members.
- Employer and school distribution models.
- Reduced dependence on physician-office appointments.
What litigation and settlement risks affect FluMist?
No major, publicly dominant patent litigation campaign is associated with FluMist comparable to the litigation surrounding leading small-molecule products. The principal legal risks are more likely to arise from:
- Patent disputes over live attenuated strain technology.
- Regulatory challenges involving labeling or administration.
- Product liability claims.
- Manufacturing or supply contracts.
- Advertising and promotional claims.
- Procurement disputes with public or institutional purchasers.
No prominent settlement agreement currently defines the U.S. competitive timetable for a direct FluMist substitute. Generic launch risk is therefore driven more by regulatory execution and manufacturing investment than by a known patent settlement date.
How strong is the FluMist patent estate?
The patent estate appears moderate to weak as a standalone barrier when measured against the age of the original product and the absence of a conventional Orange Book framework. Its commercial defensibility is stronger when patents are combined with manufacturing know-how, regulatory history, brand recognition, seasonal supply planning, and distribution access.
| Protection category | Relative strength |
|---|---|
| Original platform patents | Low to moderate, depending on jurisdiction and claim scope |
| Current product-specific patents | Requires patent-by-patent verification |
| Manufacturing know-how | Moderate to strong |
| Regulatory history | Moderate |
| Brand and provider familiarity | Moderate |
| Seasonal supply capability | Strong practical barrier |
| Direct generic substitution protection | Low |
What generic launch scenarios exist for FluMist?
Three scenarios are commercially plausible.
Scenario 1: No direct substitute
A competing nasal live attenuated vaccine does not reach the U.S. market because development costs, seasonal demand, and manufacturing complexity do not justify entry. FluMist retains its niche and grows through self-administration.
Scenario 2: A competing nasal vaccine launches
A rival develops a comparable live attenuated nasal product. Market share would depend on price, clinical evidence, supply reliability, school and pharmacy contracts, and payer coverage. AstraZeneca’s first-mover position would remain valuable but would not guarantee retention.
Scenario 3: Injectable or next-generation vaccines displace the niche
A more effective cell-based, recombinant, adjuvanted, or mRNA influenza vaccine captures younger patients and families despite requiring injection. This is the most credible long-term competitive risk because it does not require copying FluMist’s technology.
How does FluMist compare with injectable influenza vaccines?
| Attribute | FluMist | Injectable influenza vaccine |
|---|---|---|
| Administration | Intranasal | Injection |
| Needle-free | Yes | No |
| Eligible population | Generally ages 2 to 49 | Varies widely by product |
| Administration setting | Provider, pharmacy, telehealth-enabled fulfillment, or household use under authorization | Primarily provider and pharmacy settings |
| Manufacturing | Live attenuated biological product | Inactivated, recombinant, or cell-based |
| Main advantage | Convenience and needle avoidance | Broad product availability and age coverage |
| Main risk | Strain-specific performance and eligibility limits | Needle aversion and administration burden |
FluMist is best positioned as a convenience and access product. Injectable vaccines retain the broader market because they cover more age groups and include multiple technology platforms.
What is the investment outlook for FluMist?
The outlook is positive for product growth but limited for corporate revenue materiality. The 2024 self-administration decision provides a new route to market and may increase utilization among children, adolescents, younger adults, and households that avoid medical visits.
The main upside drivers are:
- Higher consumer awareness of self-administration.
- Pharmacy and telehealth adoption.
- School vaccination programs.
- Improved supply and seasonal execution.
- Greater needle avoidance.
- Stable or rising influenza vaccination demand.
The main downside risks are:
- Weak influenza seasons.
- Vaccine fatigue.
- Eligibility restrictions.
- Recurrent questions about LAIV effectiveness.
- Inventory expiry.
- Competing vaccine innovation.
- Inconsistent reimbursement or prescription access.
A reasonable business conclusion is that FluMist has a stronger commercial future than its historical sales trajectory suggests, but it remains a seasonal specialty vaccine rather than a major AstraZeneca growth engine.
Key Takeaways
- FluMist is the leading U.S. needle-free influenza vaccine and the only established intranasal option.
- FluMist Quadrivalent’s historical growth was interrupted by the 2016-2017 ACIP recommendation against LAIV.
- The 2018 recommendation reversal restored market access but did not immediately rebuild the prior commercial base.
- FDA authorization for self-administration in 2024 materially expanded distribution opportunities.
- AstraZeneca does not provide consistently separable FluMist revenue in public financial reporting.
- Direct Paragraph IV risk is limited because FluMist is a biologic vaccine, not a conventional Orange Book small-molecule drug.
- Biosimilar risk is low in the near term; manufacturing and regulatory barriers are more important than core patent expiry.
- The principal commercial threats are competing influenza vaccine technologies and better distribution, not a conventional generic launch.
- FluMist’s patent estate is less important than its live-virus manufacturing know-how, regulatory history, and seasonal supply infrastructure.
- Revenue growth is plausible, but FluMist is unlikely to become a material contributor to AstraZeneca’s consolidated sales without a major expansion in U.S. influenza vaccination.
FAQs
Can FluMist be bought without seeing a doctor?
No. FluMist remains prescription-only, although the 2024 FDA authorization allows eligible individuals to self-administer it after appropriate prescribing and dispensing procedures.
Is FluMist available for adults over age 50?
No. The authorized U.S. age range generally ends at age 49. Older adults typically use age-appropriate injectable or other approved influenza vaccines.
Does FluMist have a 12-year biologic exclusivity period remaining?
No. FluMist was approved in 2003, and its original approval predates the modern reference-product exclusivity framework applicable to newer biologics.
Is AstraZeneca likely to sell or out-license FluMist?
There is no disclosed transaction that establishes a current sale or out-license of FluMist. The product remains associated with AstraZeneca’s vaccine portfolio and U.S. commercial operations.
Could an mRNA influenza vaccine replace FluMist?
Yes. An mRNA or other next-generation vaccine could reduce FluMist’s market share if it demonstrates stronger effectiveness, broader strain coverage, easier updating, or better distribution economics. That would be platform competition rather than a direct generic challenge.
References
-
Centers for Disease Control and Prevention. (2024). Seasonal influenza vaccine supply and distribution information. U.S. Department of Health and Human Services.
-
AstraZeneca PLC. (2024). Annual report and Form 20-F for the year ended December 31, 2023. AstraZeneca.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024, September 20). FDA approves nasal spray influenza vaccine for self- or caregiver-administration. U.S. Department of Health and Human Services.
-
Grohskopf, L. A., Blanton, L. H., Ferdinands, J. M., Chung, J. R., Broder, K. R., Talbot, H. K., & Fry, A. M. (2024). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2024-25 influenza season. MMWR Recommendations and Reports, 73(5), 1-25.
More… ↓
